DESKi Secures $6M in Seed Funding to Revolutionize Early Disease Detection with AI

DESKi, an innovative healthtech startup leveraging artificial intelligence to enhance early disease detection, has raised $6 million in a seed funding round. The investment, announced today, will fuel the company’s mission to transform healthcare diagnostics by deploying AI-driven solutions for faster, more accurate identification of diseases at their earliest stages.

The funding round was led by Atlantic Bridge, with participation from Enterprise Ireland, Elkstone Ventures, and several prominent angel investors, including Dr. Fiona Pathiraja, a noted radiologist and healthtech investor. DESKi plans to use the funds to expand its AI platform, which analyzes medical imaging and patient data to detect early signs of conditions such as cancer, cardiovascular diseases, and neurological disorders.

“Early detection is critical to improving patient outcomes, yet current diagnostic tools often miss subtle signs,” said Dr. Sarah O’Connor, CEO and co-founder of DESKi. “Our AI models, trained on vast datasets of medical images and clinical records, can identify patterns invisible to the human eye, enabling earlier interventions and saving lives.”

DESKi’s Cutting-Edge Technology

DESKi’s platform integrates advanced machine learning with medical imaging technologies, such as MRI, CT scans, and X-rays, to provide clinicians with real-time diagnostic insights. The company’s proprietary algorithms, developed in collaboration with leading Irish hospitals, have shown a 30% improvement in detecting early-stage cancers compared to traditional methods. Additionally, DESKi’s system is designed to reduce false positives, minimizing unnecessary procedures and patient stress.

The startup has already partnered with several healthcare providers in Ireland and the UK, with plans to expand into the U.S. market by 2026. “Our goal is to make AI-powered diagnostics accessible globally, addressing disparities in healthcare access,” said Dr. O’Connor.

Growing Momentum in Healthtech

The investment comes amid a surge in funding for AI-driven healthtech startups. Recent reports indicate that global venture funding for AI in healthcare reached $26 billion in January 2025, with companies like Open Evidence and Biostate AI also securing significant rounds. DESKi’s focus on early disease detection aligns with this trend, as investors increasingly back solutions addressing the global shortage of skilled clinicians and rising demand for diagnostics.

“DESKi’s technology has the potential to redefine how we approach disease detection,” said Elaine Coughlan, Managing Partner at Atlantic Bridge. “Their data-driven approach and strong clinical partnerships make them a standout in the healthtech space.”

Future Plans

With the new funding, DESKi aims to accelerate clinical trials for its AI platform, targeting regulatory approvals in the EU and U.S. The company also plans to expand its team, hiring experts in AI, radiology, and bioinformatics. Additionally, DESKi is exploring applications for its technology in veterinary diagnostics, building on recent advancements in AI for animal health, such as those seen in the AI TechX consortium’s work on cattle disease detection.

The announcement has generated buzz in the healthtech community, with highlighting DESKi’s potential to disrupt diagnostics. “DESKi’s $6M raise is a game-changer for early disease detection,” noted @tech_eu, reflecting growing excitement around the startup’s vision.